Amryt Pharma (Amryt Pharma) Machinery, Furniture, Equipment : $0.0 Mil (As of Sep. 2022)

View and export this data going back to 2019. Start your Free Trial

What is Amryt Pharma Machinery, Furniture, Equipment?

Amryt Pharma's Machinery, Furniture, Equipment for the quarter that ended in Sep. 2022 was $0.0 Mil.

Amryt Pharma's annual Machinery, Furniture, Equipment increased from Dec. 2019 ($2.0 Mil) to Dec. 2020 ($3.3 Mil) and increased from Dec. 2020 ($3.3 Mil) to Dec. 2021 ($3.8 Mil).

Amryt Pharma Machinery, Furniture, Equipment Historical Data

The historical data trend for Amryt Pharma's Machinery, Furniture, Equipment can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amryt Pharma Machinery, Furniture, Equipment Chart

Amryt Pharma Annual Data

Trend

Mar12

Mar13

Mar14

Mar15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Machinery, Furniture, Equipment

Get a 7-Day Free Trial

1.48

1.46

1.98

3.33

3.83

Amryt Pharma Quarterly Data
	Dec16	Jun17	Dec17	Jun18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Machinery, Furniture, Equipment	Get a 7-Day Free Trial															-	3.83	-	-	-

Amryt Pharma Machinery, Furniture, Equipment Calculation

Machinery, Furniture, Equipment represents those fixed assets specifically dealing with tools, equipment and office furniture.

Amryt Pharma (Amryt Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Amryt Pharma PLC (NAS:AMYT) » Definitions » Machinery, Furniture, Equipment

Comparable Companies

Traded in Other Exchanges

N/A

Address

196 High Road, Dept 920A, Wood Green, London, GBR, N22 8HH

Website

http://www.amrytpharma.com

Amryt Pharma PLC is a specialty pharmaceutical company. It is focused on developing and delivering new treatments to help improve the lives of patients with rare or orphan diseases. It holds an exclusive license to sell Lojuxta (lomitapide) for adults, across the European Union and other territories including the Middle East, North Africa, Turkey and Israel. Lojuxta is used to treat a rare life-threatening disease called Homozygous Familial Hypercholesterolemia. Myalept (metreleptin) is an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients. It derives most of the revenue from the European Economic Area (EEA).